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BACKGROUND AND PURPOSE
Flecainide is a use-dependent blocker of cardiac Na+ channels. Mechanistic analysis of this block showed that the cationic form of
ﬂecainide enters the cytosolic vestibule of the open Na+ channel. Flecainide is also effective in the treatment of catecholaminergic
polymorphic ventricular tachycardia but, in this condition, its mechanism of action is contentious. We investigated how ﬂecainide
derivatives inﬂuence Ca2+-release from the sarcoplasmic reticulum through the ryanodine receptor channel (RyR2) and whether
this correlates with their effectiveness as blockers of Na+ and/or RyR2 channels.
EXPERIMENTAL APPROACH
We compared the ability of fully charged (QX-FL) and neutral (NU-FL) derivatives of ﬂecainide to block individual recombinant
human RyR2 channels incorporated into planar phospholipid bilayers, and their effects on the properties of Ca2+ sparks in intact
adult rat cardiac myocytes.
KEY RESULTS
Both QX-FL and NU-FL were partial blockers of the non-physiological cytosolic to luminal ﬂux of cations through RyR2 channels
but were signiﬁcantly less effective than ﬂecainide. None of the compounds inﬂuenced the physiologically relevant luminal to
cytosol cation ﬂux through RyR2 channels. Intracellular ﬂecainide or QX-FL, but not NU-FL, reduced Ca2+ spark frequency.
CONCLUSIONS AND IMPLICATIONS
Given its inability to block physiologically relevant cation ﬂux through RyR2 channels, and its lack of efﬁcacy in blocking the
cytosolic-to-luminal current, the effect of QX-FL on Ca2+ sparks is likely, by analogy with ﬂecainide, to result from Na+ channel
block. Our data reveal important differences in the interaction of ﬂecainide with sites in the cytosolic vestibules of Na+ and RyR2
channels.
Abbreviations
CPVT, catecholaminergic polymorphic ventricular tachycardia; NCX, Na+/ Ca2+ exchanger; RyR2, cardiac ryanodine re-
ceptor; SR, sarcoplasmic reticulum
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Introduction
Flecainide is a well-characterized blocker of sarcolemmal Na+
channels (Liu et al., 2002; Liu et al., 2003) and K+ channels
(Follmer and Colatsky, 1990; Paul et al., 2002). In addition,
ﬂecainide has been shown to be effective in the treatment of
catecholaminergic polymorphic ventricular tachycardia
(CPVT), and its action has been attributed to an ability to re-
duce inappropriate release of Ca2+ from the sarcoplasmic retic-
ulum (SR) by directly blocking open cardiac ryanodine
receptor (RyR2) channels (Watanabe et al., 2009; Hilliard et al.,
2010). However, in previous studies, we have established that
while ﬂecainide can act as a partial blocker of cytosolic to lumi-
nal ﬂux of cations in RyR2 channels, it is unable to inﬂuence
the physiologically relevant ﬂux of cations from the SR lumen
to the cytosol that occurs during Ca2+ release. As a conse-
quence, we have concluded that the mechanism of action of
ﬂecainide in CPVT depends on its ability to block Na+ channels
and does not involve a direct action on RyR2 channels (Bannis-
ter et al., 2015). This issue is important to resolve because dis-
ruption of intracellular calcium homeostasis is also linked to
dysfunction in skeletal muscle (muscular dystrophy and malig-
nant hyperthermia), smooth muscle (asthma), brain (stroke
and Alzheimer’s disease) and the endocrine system (type 2 dia-
betes mellitus). Defective RyR-mediated Ca2+ release thus is in-
volved in diseases of global prevalence and importance, and
RyR is therefore an important therapeutic target (e.g. Mackrill,
2010; Santulli and Marks, 2015).
Block of Na+ ﬂux into the cell by ﬂecainide results from
entry of the ligand from the cytosol and interaction with a
site in the cytosolic vestibule of the Na+ channel (Liu et al.,
2003). Similarly, ﬂecainide interacts with an equivalent site
within the cytosolic vestibule of RyR2 channels and gains ac-
cess to this site from the cytosol (Mehra et al., 2014; Bannister
et al., 2015). Flecainide bound in RyR2 channels inﬂuences
cation ﬂux from the cytosolic side of the channel to the SR lu-
men; a current that may contribute to charge compensation
during Ca2+ release (Gillespie and Fill, 2008), but is rapidly
displaced by cations moving in the physiologically relevant
direction (from the SR lumen to the cytosol).
Given the very different abilities of ﬂecainide to block the
equivalent, physiologically relevant, ﬂux of cations in the
Na+ and RyR2 channels, it is important to establish the corre-
sponding mechanisms governing interaction. Important
information on the molecular characteristics underlying
Na+ channel block were obtained using derivatives of
ﬂecainide with similar structural features but differing net
charge (Liu et al., 2003). As highlighted in Figure 1, at physio-
logical pH, 100% of QX-FL will be cationic while 90% of
NU-FL will be neutral. Investigations of Na+ channel block
by ﬂecainide, QX-FL and NU-FL established that block results
from the interaction of the cationic form of the molecule
with the Na+ channel (Liu et al., 2003). Flecainide has also
been shown to block hERG channels at physiologically rele-
vant concentrations (Paul et al., 2002), and QX-FL and
NU-FL have been used to demonstrate that, as is the case in
the Na+ channel, hERG block requires entry of a cationic
blocking molecule from the cell interior (Melgari et al.,
2015). In the present study, we have used QX-FL and NU-FL
to establish the mechanisms underlying the interaction of
ﬂecainide with RyR2 channels.
Our investigations demonstrated that the structural and
chemical features governing ﬂecainide interaction with Na+
channels and RyR2 channels were different. While ligand
charge was the primary determinant of blocking ability in
Na+ channels, small structural changes severely reduced the
ability of ﬂecainide to block the potential charge-
compensating, (cytosolic to SR lumen), ﬂux of cations
through RyR2 channels during Ca2+ release from the SR. Con-
sequently, the ﬂecainide derivatives give us new tools with
which to test the mechanism of action of ﬂecainide in the
regulation of Ca2+ release from the SR in CPVT. Both
ﬂecainide and QX-FL (applied inside the cell) are effective
blockers of sarcolemmal Na+ channels. Data presented here
demonstrate that while intracellular ﬂecainide might pro-
duce some reduction in a potential RyR2 channel-mediated
cation counter-current during Ca2+ release from the SR,
QX-FL will not. Therefore, intracellular QX-FL is a Na+
channel-speciﬁc ligand, and we have compared its action
with those of ﬂecainide and NU-FL on the properties of Ca2+
sparks in intact adult rat cardiac myocytes.
Methods
Cell culture and transfection
HEK293 cells (ECACC, Salisbury, UK) were cultured in
Dulbecco’s modiﬁed-Eagle medium supplemented with 10%
Tables of Links
TARGETS
Voltage-gated ion channelsa
Nav1.5 channels
Ligand-gated ion channelsb
RyR2 channels
Transportersc
NCX, Na+/ Ca2+ exchanger
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(v/v) fetal bovine serum, 2 mM glutamine and 100 μg · mL1
penicillin/streptomycin (LifeTech, Paisley, UK). Cells were in-
cubated at 37°C, 5% CO2 and 80–90% humidity at a density
of 2 × 106 per 100 mm plate (60 cm2) 24 h prior to transfec-
tion with pcDNA3/eGFP-hRyR2 (6 μg per 1 × 106 cells). After
overnight incubation, transfected cells were treated with so-
dium butyrate (2 mM) for a further 24 h before assessment
of expression (by eGFP visualization), harvesting by centrifu-
gation (500 x g AllegraR, Beckman) and storage at 80°C.
Purification of recombinant hRyR2 channels
Frozen cell pellets (typically ~50 × 106 cells) were lysed on ice
in a hypo-osmotic buffer (20 mM Tris–HCl, 5 mM EDTA;
pH 7.4) containing protease inhibitor cocktail (Roche), by
passing them 20 times through a 23 G needle. Unbroken cells
and nuclei were removed by low-speed centrifugation (1500 x
g, 10 min, 4°C, AllegraR, Beckman), and the resulting lysate
was subjected to a high-speed centrifugation (100,000 x g,
90 min, 4°C, Optima L-90 K, Beckman) to collect the
microsomal membranes. Solubilization of these membranes
was carried out (at a concentration of 2.5 mg · mL1) in a
solution containing 1 M NaCl, 0.15 mM CaCl2, 0.1 mM
EGTA, 25 mM PIPES, 0.6% (w/v) CHAPS and 0.3% (w/v)
phospatidylcholine, with protease inhibitor cocktail (Sigma)
at 4°C. Insoluble material was removed by centrifugation
(15,000 x g, 1 h at 4°C) and the supernatant loaded onto a
5–30% (w/v) continuous sucrose gradient. Fractions contain-
ing channel proteins were collected after 18 h centrifugation
at 4°C and stored at 80°C until use.
Conditions for recording single hRyR2 channels
Single hRyR2 channels were incorporated into bilayers formed
using a suspension of phosphatidylethanolamine (Avanti Po-
lar Lipids, Alabaster, AL, USA) in n-decane (35 mg ·mL1). Bi-
layers were formed in a solution containing 610 mM KCl,
20 mM HEPES (pH 7.4) in both (cis (0.5 mL) and trans (1 mL)
chambers. Channel incorporation from the cis chamberwas fa-
cilitated by the introduction of an osmotic gradient (using
200 μL 3 M KCl). On stirring, hRyR2 channels incorporate in
a ﬁxed orientation such that the cis chamber corresponds to
the cytosolic side of the channel and the trans chamber to the
luminal side (Sitsapesan and Williams, 1994; Bannister et al.,
2015). After channel incorporation, symmetrical ionic condi-
tions were re-instated by perfusion of the cis chamber with a
610mMKCl, 20mMHEPES (pH 7.4) solution. All experiments
were carried out at room temperature (20–22°C). The effects of
ﬂecainide, QX-FL and NU-FL were determined after addition of
the drug to either cis or trans chambers at concentrations indi-
cated in the text. We optimized the quantiﬁcation of block by
using conditions thatmaximize the open duration of the chan-
nel, that is, high permeant ion concentration (610 mM K+) in
the presence of 20 μM EMD 41000, a RyR2 channel agonist
shown previously to act via the caffeine-binding site (McGarry
and Williams, 1994).
Analysis of single-channel recordings
Single-channel currents were low pass ﬁltered at 5 kHz with
an eight-pole Bessel ﬁlter then digitized at 20 kHz with a
Figure 1
Chemical structures of ﬂecainide, QX-FL and NU-FL. At pH 7.4, ﬂecainide (pKa 9.3) is >99% charged; NU-FL (pKa 6.4) is >90% neutral. QX-FL is
permanently charged.
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PCI-6036E AD board (National Instruments, Austin, TX,
USA). ACQUIRE 5.0.1 (Bruxton, Seattle, WA, USA) was used
for viewing and acquisition of the single channel traces. Data
analysis was carried out using QUB v2.0.0.13 (www.qub.buf-
falo.edu). Single-channel traces of 2–3 min (containing
>3000 events) were idealized using the Segmental K-means
algorithm (Qin and Li, 2004) based on hidden Markov
models, and a dead time of 75–120 μs was imposed. In traces
where substate block was detected (by evaluation of the am-
plitude histogram), idealization was carried out using a
three state [closed (C) ↔ open (O) ↔ blocked (B)] scheme.
QUB can accurately distinguish between blocked and closed
levels and idealization using this scheme resulted in the cal-
culation of mean amplitudes, open (Po), blocked (Pb) and
closed (Pc) probabilities and mean open (To), blocked (Tb)
and closed (Tc) times. In all other instances where block
was not observed, a two-state (C↔O) scheme was used for
idealization, which yielded amplitude, Po, To and Tc as pre-
viously described (Mukherjee et al., 2012). Po values are
ﬁtted using non-linear regression. Rates of association
(Kon) and disassociation (Koff) were calculated as the recipro-
cal of To and Tb, respectively, for each drug concentration
and holding potential and ﬁtted using linear regression
(through the origin when calculating Kon for drug concen-
tration only). Due to the large difference in voltage-
dependence of block by ﬂecainide, QX-FL and NU-FL, Kon
and Koff are plotted in a dose-normalized manner. Although
different example traces are used in Figures 2 and 4, the
mean data for ﬂecainide in Figures 3 and 5 are the same as
those published in Bannister et al. (2015). These data serve
as controls against which the actions of QX-FL and NU-FL
are compared.
Figure 2
Open channel block of voltage-driven cytosolic to luminal cation ﬂux through hRyR2 channels. (A) Representative single channel traces recorded
at +40 mV in symmetrical 610 mM KCl. Openings are downwards from the closed level (black line). Channels are fully activated with 20 μM EMD
41000. The increase in blocking events (marked with a dotted line) with increasing concentration of ﬂecainide, QX-FL or NU-FL is shown in the
frequency amplitude histograms and is manifested as a decrease in Po and increase in Pb (B) Expanded frequency amplitude histograms demon-
strating the nature of the blocked states, tables above show the mean residual current (R.C.), Pb and Tb achieved with 50 μM of each drug. n is
given in each instance.
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Animals
All animal care and experimental procedures complied with
the UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act
1986, which conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes
of Health (NIH publication No. 85–23, revised 1996) and
approved by the Local Animal Ethics committee (Imperial
College Animal Welfare and Ethical Review Committee).
Rats were killed by cervical dislocation following exposure
to 5% isoﬂurane until the righting reﬂex was lost. All
procedures involving animals are reported according to
the ARRIVE guidelines (Kilkenny et al., 2010; McGrath &
Lilley, 2015).
Cardiomyocyte isolation
Ventricular myocytes from healthy adult male Sprague
Dawley rats (Charles River, UK, 250350 g) were enzymically
isolated as previously described (Sato et al., 2005). Brieﬂy,
hearts were rapidly dissected and then perfused retrogradely
using the Langendorff apparatus. Hearts were perfused se-
quentially with low calcium and a collagenase (Worthington)
solution. Ventricles were cut into small pieces and gently
minced with a Pasteur pipette. The cell suspension was ﬁl-
tered, and cardiomyocytes were allowed to settle by gravity.
Electrophysiological recordings combined with
calcium imaging
To assess the effects of intracellularly applied drug molecules
on the spatial and temporal dynamics of Ca2+ sparks,
confocal microscopy was combined with the whole-cell
voltage clamp recordings. Dual experiments were performed
on adult rat ventricular myocytes at room temperature
(20–22°C). Cells were superfused with an external physio-
logical solution of the following composition (in mM): 137
NaCl, 10 HEPES, 10 glucose, 6 KCl, 2 MgCl2, 1 CaCl2 (pH ad-
justed to 7.4 with NaOH). Borosilicate microelectrodes were
pulled to give a resistance between 2.5 and 3.5 MΩ. Vehicle,
ﬂecainide (Sigma) or its analogues QX-FL and NU-FL (all at
5 μM) were introduced into the cell cytosol via the patch
pipette. Pipettes were ﬁlled with an intracellular solution
containing either drug or vehicle in addition to membrane-
impermeant dye Fluo-3 pentapotassium salt (Invitrogen) of
the following composition (in mM): 100 K-aspartate, 15
KCl, 10 HEPES, 5 KH2PO4, 5 Mg-ATP, 5 EGTA, 0.75 MgCl2,
0.12 CaCl2, 0.04 Fluo-3-5 K
+ salt (pH adjusted to 7.2 with
2 M KOH).
After establishing a whole-cell conﬁguration, vehicle- or
drug-containing pipette solution was allowed to equilibrate
with the cytosol for 10–15 min. To facilitate steady-state SR
calcium-loading, cells underwent a series of depolarising
steps of 200 ms duration to +30 mV applied from a holding
potential of 80 mV at a frequency of 3 Hz for 30 s. Ca2+
sparks were captured following cessation of voltage clamp
stimulation. Electrophysiological recordings were carried
out using an Axopatch-1D ampliﬁer (Axon Instruments,
Wokingham, Berkshire, UK) and a Digidata1322A acquisition
system (Axon Instruments). Series resistance and whole-cell
capacitance were electronically compensated. Live cell cal-
cium imaging was performed using a laser scanning confocal
Figure 3
QX-FL and NU-FL are less potent blockers of the cytosolic to luminal current through hRyR2 channels compared with ﬂecainide. (A) Decrease in Po
at +40 mV observed with increasing concentrations of ﬂecainide, QX-FL or NU-FL with corresponding (B) rates of association (Kon, ﬁtted through
the origin) and (C) dissociation (Koff). All data points are from n = 6 separate experiments.
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system (BioRad Microscience Ltd., Hemel Hempstead, Hert-
fordshire, UK) and an inverted microscope (Nikon Eclipse
TE300, Nikon UK Ltd, Kingston Upon Thames, Surrey, UK).
Ca2+ imaging data were acquired and proc- Q13 essed using
LaserSharp2000 (Biorad) and ImageJ (National Institutes of
Health, Bethesda, MD, USA) softwares respectively.
Data and statistical analysis
Data and statistical analysis comply with the recommenda-
tions on experimental design and analysis in pharmacology
(Curtis et al., 2015). As the cardiac myocytes were prepared
from healthy adult male Sprague Dawley rats, there was no re-
quirement for randomization and blinding at this stage. For
experiments using cardiac myocytes under voltage clamp
conditions, after an initial assessment of Ca2+ handling in
control (drug-naïve) cells, the inclusion of ﬂecainide, QX-FL
or NU-FL in the patch pipette was randomly assigned. Data
analysis was performed by operators blinded to the drugs un-
der test.
In all experiments, data subjected to statistical analysis
are from at least ﬁve independent values and are reported as
mean ± SEM. The exact value of n in each dataset is given in
each instance in the corresponding ﬁgure legends. Data were
tested for normality using the D’Agostino and Pearson omni-
bus test, and normally and non-normally distributed data
were tested using unpaired Student’s t-test or
Mann–Whitney test respectively. Data were considered sig-
niﬁcant if P < 0.05. All statistical analysis was performed
using PRISM 6.0 software (GraphPad Software Inc., La Jolla,
CA, USA).
Materials
QX-FL was synthesized as described (Liu et al., 2003) while
NU-FL was synthesized using the novel procedure described
in Supporting Information. The characterization of
use-dependent block of voltage gated Na+ channels by the
synthesized QX-FL, and NU-FL used in this study is also
described in Supporting Information.
Results
The structures of ﬂecainide, QX-FL and NU-FL, together with
the proportion of eachmolecule present as cationic or neutral
species at pH 7.4, are shown in Figure 1.
Previous work (Bannister et al., 2015) has established that
ﬂecainide, present at the cytosolic face of the RyR2 channel,
can enter the cytosolic vestibule of the channel and interact
with residues in the helices lining this portion of the pore-
forming region. When bound, ﬂecainide introduces a physi-
cal and/or electrostatic barrier to the movement of cations
from the cytosolic to the luminal side of the channel. The af-
ﬁnity of interaction of ﬂecainide at this site is relatively weak,
and bound ﬂecainide is destabilized by movement of cations
in the physiologically relevant, luminal to cytosolic direc-
tion. In this report, we have examined the inﬂuence of QX-
FL and NU-FL on cation translocation in individual recombi-
nant hRyR2 channels reconstituted into planar phospholipid
bilayers and compared these effects with those of ﬂecainide.
The single channel traces in Figure 2(A) show that like
ﬂecainide, its derivatives QX-FL and NU-FL, present in the solu-
tion at the cytosolic face of the channel, are open-channel
blockers of hRyR2 when net cation current is driven cytosolic
to luminal by applying a holding potential of +40 mV across
the bilayer. The increase in occurrence of blocking events with
increasing concentration is evident in the traces themselves
and is summarised in the accompanying frequency amplitude
histograms. As is the case with ﬂecainide, QX-FL and NU-FL
do not fully occlude the hRyR2 channel pore, and residual cur-
rent continues to ﬂow with the blocking molecule bound. The
expanded frequency amplitude histograms (Figure 2(B)) high-
light a small but signiﬁcant difference (P < 0.05) in the residual
current of the blocked states produced by ﬂecainide
(19.2 ± 0.6%) and QX-FL (17.3 ± 0.5%). For NU-FL, the residual
current in the blocked state shows considerable variation.
In all cases, block was manifested as a decrease in Po
(Figure 3(A)). The KD for ﬂecainide is 13.14 ± 1.89 μM (n = 6
channels). The fully charged and neutral analogues block
considerably less effectively, and their KDs cannot be calcu-
lated from this plot. More quantitative information can be
obtained from the rates of association (Kon) and dissociation
(Koff) for ﬂecainide, QX-FL and NU-FL (n = 6 channels) shown
in Figures 3(B) and (C). Whilst no signiﬁcant differences exist
between the dissociation rates of the three compounds, rates
of ﬂecainide association are signiﬁcantly higher than those of
either QX-FL or NU-FL (all in nM1 · s1: ﬂecainide:
9.54 ± 2.20, QX-FL: 0.91 ± 0.03, NU-FL: 0.62 ± 0.05; P< 0.05).
We next examined whether cytosolic QX-FL or NU-FL was
able to inﬂuence the physiologically relevant ﬂux of cations
through hRyR2. This was carried out by reversing the holding
potential across the bilayer to 40 mV and so driving net K+
Figure 4
Neither ﬂecainide nor its derivatives block voltage driven luminal to cytosolic cation ﬂux through hRyR2 channels. Representative single channel
traces, recorded at 40 mV (luminal to cytosolic current) in the presence of cytosolic ligand (activated with 20 μM EMD41000). Openings are
upwards from the closed level (black line); no blocking events or signiﬁcant changes in Po were observed (n = 6).
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current in the luminal to the cytosolic direction (Figure 4).
These experiments demonstrate that, as previously shown for
ﬂecainide (Bannister et al., 2015), neither cytosolic QX-FL nor
NU-FL is able to inﬂuence the physiologically relevant, luminal
to cytosolic ﬂux of cations through the hRyR2 channel.
We have extended this investigation by monitoring the
effects of varying holding potential on the ability of all three
forms of ﬂecainide to block K+ ﬂux through the open hRyR2
channel. Figure 5A shows the variation in block caused by
50 μM cytosolic ﬂecainide, QX-FL and NU-FL at holding po-
tentials between ±70 mV. Under these conditions, the proba-
bility of block for both ﬂecainide and QX-FL is dependent on
potential; being more pronounced as the potential is made
increasingly positive. Voltage dependence of block by the
predominantly neutral NU-FL at 50 μM is very weak, but is
more pronounced when its association rate is increased on
raising the concentration to 200 μM (Figure 5A). These data
conﬁrm that for all three compounds block is observed only
when net K+ ﬂux is in the cytosolic to luminal direction. No
block is seen at negative holding potentials when net ﬂux is
luminal to cytosolic. In all cases, both rates of blocker associ-
ation (Figure 5B) and dissociation (Figure 5C) are inﬂuenced
by transmembrane potential.
These characterizations establish that both QX-FL and NU-
FL, present in the solution at the cytosolic face of hRyR2 chan-
nels are open channel blockers of the non-physiological ﬂux
of cations but are signiﬁcantly less effective than ﬂecainide.
None of the compounds block the physiologically relevant ﬂux
of cations when present at the cytosolic face of the channel.
Figure 6 shows the effect of adding each of the blockers to
the luminal face of the channel. Under these conditions, no
blocking events are seen either at a holding potential of
40 mV, when net cation ﬂux is in the physiologically rele-
vant luminal to cytosolic direction, or initially at +40 mV
when net ﬂux is cytosolic to luminal (top panel). These exper-
iments demonstrate that no sites of interaction for ﬂecainide
blocking molecules are present at the luminal side of the
hRyR2 channel. If a net cytosolic to luminal cation ﬂux is
maintained at +40 mV in the presence of luminal ﬂecainide
and NU-FL, brief-blocking events are apparent after several
minutes, and open-channel block is well established after
10–20 min (lower panel). The neutral forms of these com-
pounds are able to cross the membrane, passing into the solu-
tion in the cytosolic chamber and re-equilibrate here with the
cationic form (Figure 1). Only then are the cationic species
able to access the cytosolic vestibule of the channel and
partly block cytosolic to luminal cation ﬂux. Luminal fully
charged QX-FL cannot cross the bilayer or pass through
hRyR2 and, as a consequence, has no access to blocking sites
in the cytosolic vestibule.
The data presented to this point indicate that neither
QX-FL nor NU-FL are as effective as blockers of cytosolic to
Figure 5
Voltage dependence of block. (A) Plot of Po versus voltage for hRyR2 channels in the presence of 50 μM cytosolic blocker (ﬂecainide n = 11, QX-FL
n = 8, NU-FL n = 5) determined at holding potentials between ±70 mV. A higher concentration of NU-FL (200 μM, n = 5) is required to see voltage
dependence. Dose-normalized rates of (B) association (Kon) and (C) dissociation (Koff) are both voltage-dependent for ﬂecainide, QX-FL (each at
50 μM) and NU-FL (200 μM).
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luminal K+ ﬂux through the RyR2 channel as ﬂecainide and,
consequently, would be unable to inhibit any contribution
that this current might make to RyR2 channel-mediated
charge compensation during Ca2+ release from the SR. Previ-
ous investigations have established that, when present in
the cytosol, both ﬂecainide and QX-FL are potent use-
dependent blockers (UDBs) of sarcolemmal Na+ channels
(Liu et al., 2003). Their very different ability to block a poten-
tial charge compensating current through RyR2 means that
intracellular QX-FL is a powerful tool for establishing the rel-
ative contribution of Na+ channel block, and a potential ac-
tion on RyR2 channels, to ﬂecainide’s inhibition of
inappropriate RyR2 channel-mediated Ca2+ release in CPVT.
Towards this end, we examined the effects of intracellular
ﬂecainide and its derivatives on Ca2+ regulation in rat ventric-
ular myocytes. Tomeasure Ca2+ sparks, intracellular buffering
was adjusted with EGTA to prevent the occurrence of Ca2+
waves. Lowering the Ca2+-buffering capacity of the internal
solution to 0.4 mM EGTA gave optimal conditions for selec-
tively targeting SR-mediated spark activity. Before Ca2+ spark
measurement, myocytes from the control and drug treated
group were voltage-clamp stimulated for 30 s at 3 Hz from a
resting membrane potential to +30 mV in order to bring the
SR [Ca2+] to a steady-state level. Intracellular diastolic [Ca2+]
was calculated to be 77 nM. The effects of intracellular appli-
cation of ﬂecainide, QX-FL and NU-FL on Ca2+ spark parame-
ters are shown in Figure 7. A 3D topological view of the spatial
and temporal properties of Ca2+ sparks under voltage clamp
stimulation is presented in Figure 7A. Flecainide and QX-FL
were equally effective at reducing the frequency of Ca2+
sparks (Figure 7B), while NU-FL had no effect on this parame-
ter. None of the compounds had a signiﬁcant effect on spark
amplitude (Figure 7C) or mass (Figure 7D). A detailed analysis
of the inﬂuence of ﬂecainide, QX-FL and NU-FL on Ca2+ spark
parameters is presented in a table in the Supplemental
Material.
Discussion
Flecainide is a well-characterized UDB of Na+ channels (Liu
et al., 2002; Liu et al., 2003). More recently, ﬂecainide has
emerged as an effective therapeutic agent for the treatment
of CPVT both in combination with conventional
β-adrenoceptor blockade (van der Werf et al., 2011; van der
Werf et al., 2012; Watanabe et al., 2013) and as a monother-
apy (Napolitano, 2016; Padﬁeld et al., 2016).
Given its effectiveness as a Na+ channel blocker, it is
difﬁcult to envisage a therapeutic action for ﬂecainide that
does not involve this target. However, its primary action in
CPVT is considered (or has been suggested) to be on RyR2
channels, with the proposal that ﬂecainide blocks the open
channel and hence reduces, or prevents, inappropriate
RyR2 channel-mediated release of Ca2+ from the SR
(Hilliard et al., 2010).
However, recent work from our group (Bannister et al.,
2015) has established that while ﬂecainide does interact, with
relatively low afﬁnity, with a site within the cytosolic cavity
of RyR2 channels, and, when bound, can reduce the ﬂux of
monovalent cations in the cytosolic to SR luminal direction
through the channel; bound ﬂecainide is displaced by cation
ﬂux in the luminal to cytosol direction (i.e. the ﬂux corre-
sponding to the physiologically relevant movement of Ca2+
from the SR to the cytosol, to initiate contraction during
excitation-contraction coupling). Given this, the only feasi-
ble mechanism by which direct interaction of ﬂecainide with
RyR2 channels could inﬂuence SR Ca2+ release is by reducing
a monovalent cation, charge-compensating, counter-current
through the channel (Bannister et al., 2015).
While casting doubt on the therapeutic signiﬁcance of a
direct action of ﬂecainide on RyR2 channels, this observation
does raise an important mechanistic issue. In the cardiac
myocyte Na+ channels and RyR2 channels are located in dif-
ferent membrane systems. However, their orientation, the
Figure 6
Addition of ﬂecainide or its derivatives to the luminal face of channels. Representative traces of single RyR2 channels recorded at +40 mV before
and after the addition of high concentrations of blocker (top panel). QX-FL does not cross the bilayer and cannot access the channel cytosolic
vestibule. Flecainide and NU-FL are able to equilibrate across the membrane and block the cytosolic to luminal current only (lower panel). Data
were obtained from n = 3 independent experiments and were not subjected to statistical analysis.
Flecainide derivatives and ryanodine receptors BJP
British Journal of Pharmacology (2016) 173 2446–2459 2453
direction of physiologically relevant cation ﬂux through the
channels, the access route of ﬂecainide to its binding site
and the location of the binding site are all equivalent
(Figure 8A). Given this equivalence, why then is ﬂecainide a
therapeutically relevant blocker of the Na+ channel but not
of RyR2 channels?
The factors governing ﬂecainide’s blocking interaction in
the Na+ channel cytosolic cavity were revealed by studying
the blocking efﬁciency of ﬂecainide derivatives with similar
three-dimensional structure but differing net charge
(Figure 1) (Liu et al., 2003). We have used these derivatives
in the current investigation to gain new insights into the
contribution of structural and charge characteristics to the
ability of ﬂecainide to interact with RyR2 channels and to
block a potential charge-compensating, cytosolic to luminal,
monovalent cation ﬂux.
Our data demonstrate that (although with dramatically
lower afﬁnity), as is the case for ﬂecainide, both QX-FL and
NU-FL are concentration- and voltage-dependent blockers
of a potential charge compensating, monovalent cation ﬂux
through RyR2 channels. All three ligands interact within
the cytosolic vestibule of the channel pore and gain access
to this site from the cytosolic side of the channel. When
bound, the ligands do not fully occlude the RyR2 channel
pore, rather, they create a steric and/or electrostatic barrier
that limits cytosolic to luminal cation ﬂux. The different
residual currents seen, with the blocking molecules bound,
indicate that the magnitude of the barrier is dependent upon
characteristics of the blocking molecule.
Detailed investigation of the effects of ﬂecainide, QX-FL
and NU-FL on Na+ channels established that the efﬁcacy of
these ligands as blockers was determined, primarily, by net
charge rather than the structural features of the molecule
(Liu et al., 2003). The data presented here establish that this
is not the mechanism that governs the blocking interaction
with RyR2 channels. Under the experimental conditions used
in our experiments, the proportion of ﬂecainide and QX-FL
molecules that will be positively charged is essentially the
same (99% for ﬂecainide and 100% for QX-FL). However,
QX-FL is a dramatically less effective blocker of the potential
charge-compensating, cytosolic to luminal, ﬂux of K+
through RyR2 channels. This observation demonstrates that
factors other than net charge contribute to the ability of
ﬂecainide to block cytosolic to luminal cation ﬂux in RyR2
Figure 7
Effects of intracellular application of ﬂecainide and its analogues on Ca2+ spark parameters. (A) 3D topological view of the spatial and temporal
properties of Ca2+ sparks under voltage clamp stimulation. Cells were dialysed via patch pipette (10–12 min) with either vehicle control solution
containing Fluo-3-5 K+ salt, or with ﬂecainide, QX-FL or NU-FL (5 μM). Myocytes were stimulated via depolarization from 80 to +30 mV (3 Hz,
30 s) and spontaneous sparks recorded during a subsequent 20 s quiescent period. (B-D): The effect of intracellular dialysis of ﬂecainide, QX-FL or
NU-FL on mean Ca2+ spark frequency (B), amplitude (C) and mass (D). The number of cardiac myocytes used in each instance is given in paren-
theses and they were isolated from several different hearts (ﬂecainide n = 10/11, QX-FL n = 10, NU-FL n = 5; Supporting Information Table). *,
P < 0.05; signiﬁcantly different from the corresponding control (untreated) cells in each group.
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channels. This conclusion is strengthened by the observation
that NU-FL (~10% cationic) is only slightly less efﬁcient as a
blocker of RyR2 channels than QX-FL. No signiﬁcant differ-
ence exists in the rate of dissociation of the three blocking
molecules from RyR2 channels and the variation in blocking
efﬁciency of ﬂecainide and its derivatives arise from differ-
ences in their rates of association with the channel, with this
rate, in comparison with ﬂecainide, approximately 10-fold
and 15-fold lower for QX-FL and NU-FL respectively. What
characteristics of the molecules underlie this variation?
Previous work from our group has established that a wide
range of large monovalent and polyvalent cations are
concentration- and voltage-dependent blockers of cytosolic
to luminal cation ﬂux through the open RyR2 channel
(Tinker et al., 1992a,b; Tinker and Williams, 1993; Mead and
Williams, 2004; Mason et al., 2012). Given this, it is logical
to conclude that the open channel block reported here arises
from the interaction of the cationic component of ﬂecainide,
QX-FL and NU-FL, with a site within the cytosolic vestibule of
RyR2 channels. Therefore the difference in the absolute con-
centration of cationic species in ﬂecainide and NU-FL could
be a contributing factor to the differing abilities of these
molecules to block RyR2 channels. However, as the absolute
concentrations of cationic species in ﬂecainide and QX-FL
are essentially the same, other molecular characteristics must
contribute to the difference in the efﬁcacy of these blockers.
In Na+ channels, local anaesthetic antiarrhythmics, in-
cluding ﬂecainide, are stabilized within the cytosolic vesti-
bule by interactions with two aromatic residues separated
by two turns on the S6 pore-lining helix of repeat IV
(Ragsdale et al., 1994; Ragsdale et al., 1996), and high afﬁnity
binding is believed to involve cation-π interactions between
these aromatic residues and amine groups of the blockers
(Ahern et al., 2008). In RyR2 channels, cation-π interactions
are unlikely to underpin ﬂecainide block because there are
no aromatic residues in the proposed binding region (the
Figure 8
Flecainide inhibits the physiologically relevant cation ﬂux through Na+ channels but does not block Ca2+ release through RyR2 channels. Diagrams
showing the orientation of Na+ and RyR2 channels in the cardiac myocyte and the consequences of ﬂecainide interaction. (A) The topology of
sarcolemmal Na+ and sarcoplasmic reticulum RyR2 channels is equivalent. Cation ﬂuxes are indicated by arrows (Na+ inﬂux in blue, Ca2+
release in red and a charge-compensating K+ ﬂux into the SR in black). (B) (i) Simpliﬁed scheme for Na+ channel gating in the absence
of ﬂecainide. 1 – closed; 2 – open; 3 – inactivated; 4 – closed (inactivated). (ii) Simpliﬁed scheme for Na+ channel gating in the presence
of ﬂecainide. 1 – ﬂecainide enters the open channel from the cytosol; 2 and 3 – ﬂecainide prolongs the inactivated and closed (inactivated)
conformations; 4 – closed; 5. – ﬂecainide leaves the open channel. (C) (i) Simpliﬁed scheme for RyR2 channel gating in the absence of ﬂecainide. 1
– closed; 2 – open allowing Ca2+ release from the SR (red arrow) and a potential, charge compensating, cytosolic to luminal K+ counter current
(black arrow). (ii) Simpliﬁed scheme for RyR2 channel gating in the presence of ﬂecainide. 1 – closed; 2 – ﬂecainide enters the cytosolic vestibule
from the cytosol; 3 – bound ﬂecainide partly blocks the potential, charge-compensating, cytosolic to luminal K+ counter current (dotted black ar-
row); 4 – bound ﬂecainide is displaced by the physiologically relevant ﬂux of Ca2+ during release from the sarcoplasmic reticulum.
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lower cytosolic vestibule of the channel) (Bannister et al.,
2015). The variation in blocking efﬁciency of ﬂecainide and
its derivatives suggests that the capacity of the molecules to
act as hydrogen bond acceptors or donors may be important
in determining their ability to bind in the RyR2 channel cyto-
solic cavity. Considering functional group differences, the
secondary amine ﬂecainide can form two hydrogen bonds
with the piperidine ring as its conjugate acid, whereas
NU-FL, a tertiary amine, can form only one. QX-FL, as a qua-
ternary compound, has no hydrogen bonding capacity in
that region. Small structural differences among ﬂecainide,
QX-FL and NU-FL (Figure 1) may also contribute to the likeli-
hood of interaction with RyR2 channels. The bonding
around the ring nitrogen in QX-FL and the cationic forms of
ﬂecainide and NU-FL is not identical, and steric encumbrance
around this atom may result in reduced efﬁcacy.
Crucially, the consequence of ﬂecainide interactionwith the
Na+ channel differs from that with RyR2 channels in one very
important way; although, access to the ﬂecainide binding site
in Na+ channels requires the channel to be open, once bound,
ﬂecainide interacts preferentially with the inactivated closed
conformation of the channel, prolonging this state, thereby
limiting the channel’s availability for further activation (Liu
et al., 2002). This limited egress of ﬂecainide from the Na+ chan-
nel facilitates the accumulation of block (or use-dependence)
with repetitive depolarizations of the cell (Liu et al., 2003).
Therefore, in Na+ channels, ﬂecainide does not merely act as a
blocking substrate, it also effectively alters the gating of the
channel. Gating of RyR2 channels involves transitions between
open or closed states but, unlike the Na+ channel, the RyR2
channel does not need to pass through an inactivated state, so
in these channels, ﬂecainide acts simply as an open-channel
partial blocker of cytosolic to luminal cation ﬂux, and use-
dependent block does not occur. The absence of an effect on gat-
ing, and the low afﬁnity with which ﬂecainide binds within the
cytosolic vestibule of RyR2 channels, means that bound
ﬂecainide is readily displaced by the physiologically relevant, lu-
minal to cytosolic, ﬂux of Ca2+ from the SR during E-C coupling
(Bannister et al., 2015). The mechanisms governing ﬂecainide
interaction in Na+ and RyR2 channels are summarized in
Figure 8(B) and (C) respectively.
The data presented here and in Bannister et al. (2015) es-
tablish that the only way in which ﬂecainide could act di-
rectly on RyR2 channels to inhibit Ca2+ release would be via
a very small reduction of an RyR2 channel-mediated counter
current. The demonstration that QX-FL is essentially without
effect on this current identiﬁes this ligand as a tool with
which to examine if counter current inhibition contributes,
in any way, to ﬂecainide’s therapeutic action in CPVT. Intra-
cellular QX-FL and ﬂecainide are both highly effective
blockers of the sarcolemmal Na+ channel (Liu et al., 2003,
Supporting Information Figure S2), while even the small,
potential, effect of ﬂecainide on RyR2 channel-mediated
counter-current will be absent with intracellular QX-FL. Consis-
tent with the conclusion that the action of ﬂecainide on Ca2+
handling in cardiac myocytes results solely from inhibition of
the Na+ channel, intracellular ﬂecainide and QX-FL have equiv-
alent effects on Ca2+ sparks. NU-FL, a considerably less efﬁcient
Na+ channel blocker, has no effect on Ca2+ handling.
In intact cardiomyocytes, whole-cell patch clamp-
mediated intracellular application of 5 μM ﬂecainide, and
QX-FL, but not NU-FL, decreased spark frequency with no ef-
fect on spark amplitude and mass (Figure 7 and Supporting
Information Table). These data suggest that it is the charged
form of ﬂecainide that mediates this effect and corroborate
and extend previous ﬁndings that ﬂecainide suppresses Ca2+
spark frequency (Sikkel et al., 2013a). Taken together with
the present investigations that conﬁrmed a lack of effect of
these concentrations of ﬂecainide and QX-FL on the physio-
logically relevant luminal-to-cytoplasmic ion ﬂux through
RyR2 channels and, in the case of QX-FL, any inhibition of
a potential charge-compensating cytosolic-to-luminal K+ ﬂux
(Figures 4–6), these data support the conclusion that the only
mode of action underpinning ﬂecainide’s efﬁcacy in CPVT
patients is the inhibition of INa (Liu et al., 2011; Sikkel et al.,
2013a; Bannister et al., 2015). In addition, our demonstration
that QX-FL is a Na+ channel speciﬁc ligand, yet has identical
effects to ﬂecainide on Ca2+ spark parameters (Supplementary
Table) reinforces this conclusion.
Sikkel et al. (2013a) showed that the ﬂecainide-mediated
reduction in Na+ inﬂux into the cardiomyocyte can, via the
enhancement of Ca2+ efﬂux through the Na+/ Ca2+ ex-
changer (NCX), decrease [Ca2+]i in the vicinity of the RyR2
channels and thus reduce the frequency of spontaneous SR
Ca2+ release events. These authors also showed that this was
a class effect of INa blockers, and moreover, ﬂecainide caused
no reduction in SR Ca2+ leak when INa was eliminated by al-
tering the holding potential via a voltage clamp. By amalgam-
ating these ﬁndings with their existent hypothesis that
ﬂecainide’s mechanism of action was dependent on direct ef-
fects on INa and through direct interaction with RyR2 chan-
nels, Steele and co-workers proposed a ‘triple mode’ of
ﬂecainide action, namely, via its direct effects on INa and
RyR2 channels and an indirect effect on NCX (Steele et al.,
2013). The present investigations, which corroborates
previous work by Bannister and colleagues (Bannister et al.,
2015), present the unequivocal demonstration that
ﬂecainide does not have a direct effect on luminal-
to-cytosolic Ca2+ ﬂux through RyR2 channels, and funda-
mentally challenges reports that ﬂecainide efﬁcacy in RyR2
channel- and CSQ-mutation linked CPVT patients is due to
an additive effect of INa inhibition and a direct block of RyR2
channels (Watanabe et al., 2009; Hilliard et al., 2010; Galimberti
and Knollmann, 2011; Hwang et al., 2011; Lee et al., 2012).
Further corroborating the lack of direct effect of ﬂecainide on
RyR2 channel-mediated Ca2+ release, Supporting Information
Figure S3 shows the persistence of RyR2 channel-dependent
spontaneous Ca2+ release events in Nav1.5-null HEK (HEK) in
the presence of ﬂecainide (5 μM).
The contention that ﬂecainide is less effective in
inhibiting RyR2 channels under circumstances that promote
higher spark frequency (i.e. conditions of Ca2+ overload)
(Steele et al., 2013; Sikkel et al., 2013b) is not applicable here
because the present studies in intact control cells are charac-
terized by comparable Ca2+ spark frequencies with those re-
ported by Hilliard et al. (≈1.5 versus 0.8, respectively),
suggesting similar SR Ca2+ loading. Adding to the confusion,
the same group has recently described the increased potency
of ﬂecainide in suppressing intracellular Ca2+ waves in
permeabilized cardiomyocytes following manoeuvres that
increase Ca2+ spark frequencies (Savio-Galimberti and
Knollmann, 2015).
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We have established that the principal action of
ﬂecainide in CPVT is not via a direct interaction with
RyR2 channels. Our data support a model of ﬂecainide
action in which Na+-dependent modulation of intracellular
Ca2+ handling attenuates RyR2 channel dysfunction in
CPVT. These ﬁndings are crucial as they will contribute to
the rational design of improved therapies and prevent the
clinical misuse of ﬂecainide in the treatment of phenotyp-
ically similar but mechanistically distinct arrhythmias.
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Figure S1 Heterologous expression of functional Nav1.5
channels in HEK293 cells. (A) A proﬁle of Coomassie stained
proteins following SDS-PAGE (left) and the corresponding
immunoblot of Nav1.5 channels in H-Flp/ Nav1.5 cells
(right)(see Supplementary Methods). The Nav1.5-null H-Flp
host cell line was used as control. (B) Combined immunoﬂu-
orescence and brightﬁeld images shows recombinant Nav1.5
channels at plasma membranes (red) in H-Flp/ Nav1.5 cells
and conﬁrmed the absence of Nav1.5 protein in control
H-Flp cells. Nuclei were counterstained with DAPI (blue).
Scale bar is 20 μm. (C) Voltage-dependent activation of the
Na+ current (INa) in H-Flp/ Nav1.5 cells was measured using
100 ms, 10 mV increment steps between 80 and +60 mV
from a holding potential of 120 mV.
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Figure S2 Use-dependent block (UDB) of voltage gated Na+
channel current (INa) by ﬂecainide analogues, NU-FL and
QX-FL. INa traces prior to UDB (in the absence of ﬂecainide
(A) or during a 1 Hz protocol (B)) and at steady-state UDB fol-
lowing the completion of a 10 Hz activation protocol in the
presence of NU-FL or QX-FL. (C) Data for 10 Hz UDB,
expressed as a fraction of non-blocked, steady state INa is
given as mean ± SEM (n = 8 (10 μM NU-FL), n = 9 (100 μM
NU-FL and 10 μM QX-FL).
Figure S3 Flecainide has no effect on spontaneous Ca2+ re-
lease transients, through hRyR2 channels, in transfected
HEK293 cells. (A) Sample traces showing spontaneous
Ca2+ release events from three different cells expressing
hRyR2 channels in the absence and in the presence of
ﬂecainide (5 μM). Flecainide had no effect on Ca2+ spike
amplitude (B), duration (C), inter-transient duration (D)
or frequency (E) (n = 8).Supplementary Table. Ca2+ spark
parameters.
Flecainide derivatives and ryanodine receptors BJP
British Journal of Pharmacology (2016) 173 2446–2459 2459
